We’ve been talking about this for a long time now, so we’re really pleased to have finally changed our name.  Previously known as LPLD Alliance we hope our new name captures the essence both of managing the condition on a daily basis, and the work of the charity on behalf of people affected by…

In February 2019 the European Medicines Agency  licenced Waylivra / Volanesorsen as “an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate”. You can read more about the EMA’s decision below. Read here…